







In this talk, I will cover a few topics. First, I will describe some of the cutting-edge science 
that’s underway and how we are applying it within Synthetic Genomics, not specifically 
on specialty crops as defined, but on low-acreage or potential crops of the future. Many 
of these concepts will apply to specialty crops.
We can think about progress in synthetic biology, much in the way that children progress 
through school (Figure ). First, in 995, whole-genome sequences were published for 
two simple bacterial species (Haemophilus influenzae and Mycoplasma genitalium), which, 
in the late 990s, were followed by publication of several plant genomes, culminating 
in 00 with the publication of the draft sequence of the human genome. That was 
equivalent to learning to read, as in early grade school, begging the question: “If we can 
read the genetic code, can we begin to write it?” In 003, the synthesis of a small viral 
genome was achieved, at a little over 5,000 base pairs. In 006, effort was initiated to 
chemically synthesize a bacterial cell. The result was published by J. Craig Venter Institute 
researchers in 00: fundamentally, this organism came from nature and we recapitulated 
it with a few additional sequences.
Writing Stories
What’s important now is to take the tools that we have developed in reading and writ-
ing to create our own stories. This is where the design aspect gets interesting in terms 
of developing crops that not only are more robust and higher yielding, but can be more 
beneficial from a health standpoint. Focusing on some of the tools, Figure  shows a 
simplified diagram of the process used to produce the first chemically synthesized cell, 
which has a genome of about . megabases, i.e. over a million base pairs. When this 
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Figure . Approach used to synthesize a Mycoplasma mycoides cell.
Figure . Progress in synthetic biology.
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Figure 3. DNA synthesis/assembly methods: alternatives enabling
combinatorial assembly.
Figure 4. Automation of DNA assembly.
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project was undertaken, the largest DNA assemblies that had been produced were of 
about 30 kilobases—about a thirty-fifth the size. One of the challenges was stitching 
DNA together accurately in these large assemblies. Several methods were developed, but 
constructing these assemblies was only part of the problem; the next question was how 
to activate it and give it life. Methods were developed for handling whole genomes and 
transplanting them into related recipient cells that essentially served as the birthplace 
for the new genome. And again, in this case, much like a virus takes over the host cell, 
the transplanted genome was replicated, transcribed and translated, producing marked 
synthetic cells as in Figure .
Simple Methods for DNA Assembly
Important for future progress was the development of some simple, but powerful, methods 
for assembling DNA. The right-hand side of Figure 3 illustrates the Gibson assembly 
method, now utilized in many laboratories; Dan Gibson’s insight was to use DNA-repair 
mechanisms as the basis for developing an in vitro mix that is isothermal and reliable. This 
method is quite amenable to automation because of its relative simplicity, and Figure 4 
shows a unit we received in December of 0, the prototype of a benchtop instrument 
that will allow all laboratories to synthesize genes or even larger segments of DNA.
The instrument is loaded with the oligonucleotides encoding the gene of interest, a 
button is pushed and overnight the constructs are made. And this has actually been used 
for rapid production of influenza vaccines. SGI has a number of partnerships with leading 
companies, including Novartis Vaccines to develop a faster method to synthesize vaccine 
seeds so that Novartis can get a supply of influenza vaccine to the market more rapidly. 
The importance of this was illustrated in 009, when the HN epidemic was of great 
concern. As Figure 5 shows, the number of cases was growing exponentially before the 
vaccine became available. The reason it took so long to get the vaccine to market was 
both a function of a long process to develop the vaccine seeds as well as low yields with 
the HN virus.
There needed to be a better solution, so the Centers For Disease Control Board/ Bio-
medical Advanced Research and Development Authority (CDC/BARDA) is funding 
Novartis and Synthetic Genomics to develop a better, faster and more reliable method 
for, not only producing vaccines for seasonal flu cases, but also to have a method that can 
be used for responses to pandemics. We have been successful in taking what is typically a 
six-week process using classical genetics to isolate virus-vaccine seeds to a process where, 
now, when the World Health Organization releases information about a strain, we take 
that sequence and, using our assembly methods, can synthesize the DNA constructs in 
about twelve hours, achieve infection of mammalian cells and recover active virus seeds 
in five to six days. This shortens the process by about six weeks. In the long-term, we 
will be able to survey all of the possible materials out there and bank the viral gene seg-
ments for assembly overnight when called for. This was recently reported with the H7N9 
strain in China, which is currently not available in the United States. However, BARDA 
requested it and we were successful in assembling and producing a vaccine seed without 
having those viral strains available.
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Figure 5. Synthetic Genomics case study: Influenza vaccine.
(Data provided by Phil Dormitzer at Novartis Vaccines & Diagnostics.
http://www.cdc.gov/hnlflu/estimates_009_hn.htm)
These improvements in speed are important, but so too is accuracy. We have worked 
hard to develop methods to weed out errors that are inherent with oligonucleotides, the 
60-base-pair segments that are the building blocks for genes and, ultimately, genomes. 
They can be only 60 percent to 70 percent pure, therefore, if large numbers are stitched 
together, assembly errors are almost guaranteed, which can be problematic. To address 
this, we have used bioinformatic capability to develop error-correction methods that we 
now incorporate routinely. This allows us to accurately assemble DNA segments of up 
to seven kilobases without intermediate sequencing to verify accuracy.
Another important factor is cost. At the time, building the genome of Mycoplasma 
mycoides cost about $ million in reagents alone. It was a fascinating project, but not 
something that would be taken on routinely because of the necessary expenditures. This 
field as a whole depends not only on improved accuracy, but on lowering the cost of DNA 
assembly. Figure 6 shows the exponential decrease that has occurred in sequencing costs 
since 990, which has fostered applications of “omics” technologies.
We haven’t seen the same reduction in cost of gene synthesis (Figure 6). We and scientists 
in several other labs are working on methods that involve ultra-low-cost DNA sources 
from microchips as well as next-generation sequencers that allow retrieval of validated 
correct sequences to begin assemblies. If successful, these methods could lower the cost 
by at least an order of magnitude, bringing the assembly cost down to a penny or two per 
base, presenting the possibility of new ways of improving specialty and other crops. 
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Figure 6. Cost trends: DNA synthesis and assembly.
(Adapted from R. Carlson, www.synthesis.cc.
Includes SGI Projection.)
Trait Discovery and Pathway Engineering
Over the past six years, we have developed a web-based scalable comprehensive bioin-
formatics platform to allow not only computational biologists, but also novice users, to 
analyze genomic information and to use that information in design and construction 
of DNA assemblies for recombinant cells. And we have done an extensive amount of 
biodiscovery and characterization of fungal, plant and algal genomes, which increases the 
diversity of information available for our work.
Using our proprietary enrichment and isolation methods, we have acquired some 
4,000 microbial isolates—associated with wild grasses—that have been screened for 
various properties. One of the interesting things that came out of this was the idea that, 
with these bioinformatics methods and knowledge of gene structure/function, we could 
then use bioinformatics as an assay in the discovery effort. With a view to discovering 
new Bt-type insecticidal toxins, we took our Bacillus isolates—a subset of about 00 in 
5
number—and isolated the plasmid DNA potentially encoding such toxins, pooled those 
plasmids, went through a next-generation sequencing effort and then were able to assemble 
and annotate that information. Within a six-week period, we discovered fifty full-length 
novel Bt genes. This pilot test demonstrated the potential utility of this extensive amount 
of information when analyzed with the new tools.
We now have the ability to efficiently and cost-effectively assemble DNA structures 
from starting-material oligonucleotides. We can now construct digitally designed protein 
variants rather than employ traditional methods that involve either random changes such 
as error-prone PCR or gene shuffling or site-directed mutagenesis, which allows us to 
make base-pair nucleotide changes, but only in specific regions. Being able to design this 
on the computer gives us unlimited flexibility.
We had an enzyme for which we were trying to modify the substrate specificity to induce 
a desired carbon-carbon bond-cleavage reaction. We had an enzyme that performed other 
chemistry on those identical substrates and then we had “enzyme A,” which in fact did not 
work on those substrates but catalyzed the reaction of interest. Through protein modeling, 
we identified a number of changes that would be beneficial within and outside the active 
site and made a set of 88 protein variants, which we screened for function (Figure 7). 
Within one round, we obtained ten mutants that worked on both of the substrates of 
interest. In essence, we had engineered the desired change in substrate specificity.
Molecular Breeding for Specialty Crops
One of the foci of our AgraCast subsidiary is the development of castor-oil plant (Ricinus 
communis) as a source of specialty chemicals. Castor is of interest due to its high content 
Figure 7. Engineered enzyme activity results: the substrate range of the target enzyme 
was modified creating the desired activity.
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of ricinoleic acid, a hydroxylated fatty acid that provides a platform for producing branch-
chain chemicals. It is used by BASF to produce lubricants, for example. However, a 
barrier to broader scale adoption is lack of availability, lack of consistency and high cost. 
Although it grows wild in Texas and in Mexico, commercial production is mainly in 
India by small farmers with relatively low yields, one to two tons per hectare. Typically, 
it is harvested manually because of the plant’s architecture. Several years ago, we began 
both classical and molecular breeding programs to identify plants with larger racemes 
and higher yields (Figure 8). We are up to about four tons per hectare. 
Algae as a Major Crop of the Future
By FAO estimates, we will need to increase the food supply significantly in the foresee-
able future, and we will have to do it without accessing more arable land, usage of which 
has been stagnant for decades. That, coupled with issues associated with climate change, 
increasingly important issues around water availability and the fact that we are seeing 
increases in demand for animal protein that are primarily correlated with increased eco-
nomic development, we see the need not only for increased productivity of our major 
crops, but also of new crops that can be cultivated on non-arable lands with minimal 
inputs of fresh water.
We have had a collaboration with Exxon-Mobil since 009, researching algae for use 
as biofuels, but we may see this commercially utilizable in production of algal-based 
proteins. The potential is shown in Figure 9: algae—even the current forms—are much 
more efficient producers of protein than are terrestrial counterparts. Our characterizations 
show that algal protein provides complete sources of amino acids and are highly digestible. 
Major barriers associated with algae as commercial sources of protein include developing 
domesticated species that will grow robustly in the wild. We see a need to use synthetic 
genomics techniques to combine beneficial traits that have utility under specialized con-
ditions and combine them with photosynthetic efficiency, to allow us to channel carbon 
to target molecules and show improved tolerance of environmental stresses. One of the 
most significant things that we’ll be reporting on towards the end of 03 is research to 
improve photosynthetic efficiency.
Figure 0 shows that when algae grow in dense culture, light becomes limiting and 
overall productivity decreases. In part, this is because, when light is low the algae acclimate 
and build larger antennae that shade their neighbors. We have engineered semisynthetic 
algae that are deregulated in their response to light, allowing significantly more light to 
penetrate the culture without compromising the photosynthetic processes and functional-
ity of the cell. We’ve also taken similar steps to increase lipid productivity in just a matter 
of a few months, again based on bioinformatics and our ability to modify biosynthetic 
pathways. Our algal research is at an early stage, but our synthetic genomics techniques 
give the ability to accelerate the developmental process. Ultimately, I think that we will 
see large-scale algal-production facilities providing a growing share of protein requirement 
in the future.
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Figure 8. Molecular-breeding rationale and targets: the molecular-breeding
approach developed for large-acreage crops will be increasingly applied to
specialty crops like castor bean.
Figure 9. Algae is the best, scalable production system in a land-, water-, and carbon-
constrained world (data based on various literature reports).
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Figure 0. Engineering algae for improved photosynthetic efficiency: increased light 
penetration and improved photosynthetic efficiency.
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